Peyramond D, Denoyel G A, Bertrand J L, Bertoye A
Pathol Biol (Paris). 1982 Jun;30(6 Pt 2):596-602.
We evaluated Acyclovir therapy in 16 immunodeficient children with varicella (7 cases) and zoster (9 cases) in a controlled open study. infections were serious in 12 patients. Each patient had daily clinical, biological and virological tests. Sixty minutes intra-venous infusions of Acyclovir were given three times a day (5 to 10 mg/kg/8 hours) for 6 ou 11 days. All patients who received therapy before the first four days, ahd a more rapid cessation of new vesicles formation and more rapid scaring, than those with delayed treatment. Ten controlled children had accelerated clearance of viral antigens from vesicles. In 15 cases, virus was not isolated after the third day. Two children with varicellous interstitial pneumonia died, 8 and 25 days after the end of treatment. Fourteen patients recovered in 8 to 10 days. No relapses of varicella-zoster virus infections had been observed 1 to 14 months after therapy. The drug was well-tolerated, but supervising of renal functions is necessary. Acyclovir had a good therapeutic efficacy to treat chickenpox and shingles in the immunocompromised patients.
在一项对照开放性研究中,我们评估了阿昔洛韦对16名患有水痘(7例)和带状疱疹(9例)的免疫缺陷儿童的治疗效果。12名患者的感染情况较为严重。每位患者每天都要进行临床、生物学和病毒学检测。阿昔洛韦采用静脉滴注,60分钟输完,每天3次(5至10毫克/千克/8小时),持续6或11天。所有在头四天内接受治疗的患者,与治疗延迟的患者相比,新水疱形成的停止更快,结痂也更快。10名对照儿童水疱中病毒抗原的清除加快。15例在第三天后未分离出病毒。两名患有水痘性间质性肺炎的儿童在治疗结束后8天和25天死亡。14名患者在8至10天内康复。治疗后1至14个月未观察到水痘-带状疱疹病毒感染复发。该药物耐受性良好,但有必要监测肾功能。阿昔洛韦对免疫功能低下患者的水痘和带状疱疹具有良好的治疗效果。